利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

13 条记录 (耗时 0.036 秒)

    COMPOSITION FOR TREATMENT OF TUBERCULOSIS
    1.
    发明申请
    COMPOSITION FOR TREATMENT OF TUBERCULOSIS 有权
    用于治疗结肠癌的组合物

    公开(公告)号：US20110053880A1

    公开(公告)日：2011-03-03

    申请号：US12808801

    申请日：2008-11-25

    申请人： Martin Fussenegger ,  Wilfried Weber ,  Ronald Schoenmakers

    发明人： Martin Fussenegger ,  Wilfried Weber ,  Ronald Schoenmakers

    IPC分类号： A61K31/7028 ,  A61K31/44 ,  A61K31/175 ,  G01N33/53 ,  A61P31/06

    CPC分类号： A61K31/17 ,  A61K31/4409 ,  A61K45/06 ,  A61K2300/00

    摘要： The invention relates to a pharmaceutical composition comprising a compound preventing EthR from binding to the ethA promoter, for example a compound of formula 1 wherein R1 is optionally substituted phenyl or optionally substituted pyridyl; R2 (CH2)n wherein n is 1, 2, 3 or 4; R3 is CH3(CH2)m wherein m is 0, 1, 2 or 3; X1 is O, S, NH, N(CH3) or CH2; and X2 is O, S or NH; in particular 2-phenylethyl butyrate, and a thioamide or thiourea of formula 2 wherein R4 is optionally substituted phenyl, optionally substituted pyridyl, optionally substituted indolyl, —NR7R8; or —NH—N═CH—R9; and substituents R5 to R9 have the meanings indicated in the description, in particular ethionamide. The pharmaceutical composition is useful, e.g., in the treatment of multidrug-resistant tuberculosis.

    摘要翻译： 本发明涉及包含防止EthR与ethA启动子结合的化合物的药物组合物，例如式1的化合物，其中R 1是任选取代的苯基或任选取代的吡啶基; R2（CH2）n，其中n为1,2,3或4; R3是CH3（CH2）m，其中m是0,1,2或3; X 1是O，S，NH，N（CH 3）或CH 2; X2是O，S或NH; 特别是丁酸2-苯基乙酯和式2的硫代酰胺或硫脲，其中R 4是任选取代的苯基，任选取代的吡啶基，任选取代的吲哚基，-NR 7 R 8; 或-NH-N = CH-R 9; 并且取代基R 5至R 9具有在说明书中指出的含义，特别是乙二胺。 药物组合物可用于例如治疗多重耐药性结核病。

    Composition for treatment of tuberculosis
    3.
    发明授权
    Composition for treatment of tuberculosis 有权
    用于治疗结核病的组合物

    公开(公告)号：US09050295B2

    公开(公告)日：2015-06-09

    申请号：US12808801

    申请日：2008-11-25

    申请人： Martin Fussenegger ,  Wilfried Weber ,  Ronald Schoenmakers

    发明人： Martin Fussenegger ,  Wilfried Weber ,  Ronald Schoenmakers

    IPC分类号： A61K31/17 ,  A61K31/4409 ,  A61K45/06

    CPC分类号： A61K31/17 ,  A61K31/4409 ,  A61K45/06 ,  A61K2300/00

    摘要： The invention relates to a pharmaceutical composition comprising a compound preventing EthR from binding to the ethA promoter, for example a compound of formula 1 wherein R1 is optionally substituted phenyl or optionally substituted pyridyl; R2 (CH2)n wherein n is 1, 2, 3 or 4; R3 is CH3(CH2)m wherein m is 0, 1, 2 or 3; X1 is O, S, NH, N(CH3) or CH2; and X2 is O, S or NH; in particular 2-phenylethyl butyrate, and a thioamide or thiourea of formula 2 wherein R4 is optionally substituted phenyl, optionally substituted pyridyl, optionally substituted indolyl, —NR7R8; or —NH—N═CH—R9; and substituents R5 to R9 have the meanings indicated in the description, in particular ethionamide. The pharmaceutical composition is useful, e.g., in the treatment of multidrug-resistant tuberculosis.

    摘要翻译： 本发明涉及包含防止EthR与ethA启动子结合的化合物的药物组合物，例如式1的化合物，其中R 1是任选取代的苯基或任选取代的吡啶基; R2（CH2）n，其中n为1,2,3或4; R3是CH3（CH2）m，其中m是0,1,2或3; X 1是O，S，NH，N（CH 3）或CH 2; X2是O，S或NH; 特别是丁酸2-苯基乙酯和式2的硫代酰胺或硫脲，其中R 4是任选取代的苯基，任选取代的吡啶基，任选取代的吲哚基，-NR 7 R 8; 或-NH-N = CH-R 9; 并且取代基R 5至R 9具有在说明书中指出的含义，特别是乙二胺。 药物组合物可用于例如治疗多重耐药性结核病。

    STIMULI-RESPONSIVE HYDROGEL
    5.
    发明申请
    STIMULI-RESPONSIVE HYDROGEL 审中-公开
    刺激性水凝胶

    公开(公告)号：US20110151006A1

    公开(公告)日：2011-06-23

    申请号：US12996492

    申请日：2009-06-05

    申请人： Wilfried Weber ,  Martin Fussenegger ,  Ronald Schoenmakers

    发明人： Wilfried Weber ,  Martin Fussenegger ,  Ronald Schoenmakers

    IPC分类号： A61K9/14 ,  A61K38/18 ,  A61P5/00

    CPC分类号： A61K38/52 ,  A61K38/1866 ,  A61K47/549 ,  A61K47/552 ,  A61K47/58 ,  A61K47/60 ,  A61K47/62 ,  A61K47/6903

    摘要： The present invention relates to a hydrogel comprising a polymer, a first polypeptide and a polypeptide binding partner, wherein the polypeptide binding partner is a second polypeptide, a nucleic acid or a small molecule, and wherein the interaction between the first polypeptide and the polypeptide binding partner stabilizes the hydrogel and is modulated by the addition of a modulating compound. A drug may be physically entrapped in the hydrogel, bound to the polymer forming the hydrogel structure, or bound to the first polypeptide or the polypeptide binding partner, and then be set free on addition of the modulating compound. Such a hydrogel comprising a drug may be injected into a patient, and drug release modulated by orally administering the modulating compound.

    摘要翻译： 本发明涉及包含聚合物，第一多肽和多肽结合配偶体的水凝胶，其中多肽结合配偶体是第二多肽，核酸或小分子，并且其中第一多肽和多肽结合之间的相互作用 配偶体稳定水凝胶，并通过加入调节化合物进行调节。 药物可以被物理地包埋在水凝胶中，与形成水凝胶结构的聚合物结合，或者与第一多肽或多肽结合配偶体结合，然后在加入调节化合物时释放。 包含药物的这种水凝胶可以注射到患者体内，并通过口服施用调节化合物调节药物释放。